8 completed, 1 terminated, 1 withdrawn. 6 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 5, Terminated 1 |
| Phase 2 | 4 | Completed 3, Withdrawn 1 |
Follow GW 876008: new trials by email Literature Review of GW 876008 trials Research Report on GW 876008
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response After Dosing With GW876008 And Gsk561679 GW876008 and GSK561679 - Irritable Bowel Syndrome | Phase 2 | Withdrawn | GlaxoSmithKline | 2007-08-01 | 2015-03-02 | |
| A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Contraceptive Pills GW876008, COC - Social Phobia | Phase 1 | Terminated | GlaxoSmithKline | 4 | 2007-06-08 | 2017-08-04 |
| A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder GSK561679 tablet, GW876008 tablet, alprazolam - Social Phobia | Phase 1 | Completed | GlaxoSmithKline | 35 | 2007-03-27 | 2017-08-04 |
| A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects. placebo, lorazepam, GW876008 - Healthy Subjects | Phase 1 | Completed | GlaxoSmithKline | 26 | 2007-03-01 | 2010-10-15 |
| Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome GW876008 - Irritable Colon | Phase 2 | Completed | GlaxoSmithKline | 10 | 2006-12-08 | 2017-08-08 |
| An Investigation To Determine The Potential Interaction Effect Between GW876008 And Midazolam. midazolam, GW876008 - Healthy Subjects | Phase 1 | Completed | GlaxoSmithKline | 25 | 2006-12-01 | 2009-05-18 |
| Treatment Of Patients With Social Anxiety Disorder GW876008, paroxetine - Social Phobia | Phase 2 | Completed | GlaxoSmithKline | 299 | 2006-11-09 | 2017-07-11 |
| A Study To Investigate The Metabolism Of GW876008 In Smokers Compared To Non-Smokers. GW876008 - Healthy Subjects | Phase 1 | Completed | GlaxoSmithKline | 26 | 2006-11-01 | 2009-05-18 |
| Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers GW876008 200mcg, GW876008 20mcg, Placebo - Irritable Colon, Irritable Bowel Syndrome (IBS) | Phase 1 | Completed | GlaxoSmithKline | 25 | 2006-11-01 | 2017-05-16 |
| Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome GW876008, Placebo - Irritable Bowel Syndrome (IBS) | Phase 2 | Completed | GlaxoSmithKline | 133 | 2006-10-14 | 2018-01-31 |
Irritable Bowel Syndrome (4) · Phobia, Social (3) · Anxiety Disorders (1) · Depression (1)
GlaxoSmithKline (10)
United States (6) · Canada (2) · United Kingdom (2) · Finland (1) · Germany (1) · Norway (1) · South Africa (1) · Spain (1) · Sweden (1)